• Nem Talált Eredményt

kölcsönhatása Sugárzásés élő anyag

N/A
N/A
Protected

Academic year: 2022

Ossza meg "kölcsönhatása Sugárzásés élő anyag"

Copied!
17
0
0

Teljes szövegt

(1)

kölcsönhatása

(2)

Müller, M., Durante, M., Stöcker, H., Merz, F. & Bechmann, I. Modelingradiation effects at the tissue level. EurPhysJ D60, 171 176 (201 0).(graphics kindly provided by Dr.Andrea Ottolenghi, University of Pavia, Italy)

2

(3)

Hall, E. J. & Giaccia, A. J. Radiobiology for the radiologist. (Wolters Kluwer Health/Lippincott Williams & Wilkins, 2012 Figure 1.4

(4)

Hall, E. J. & Giaccia, A. J. Radiobiology for the radiologist. (Wolters Kluwer Health/Lippincott Williams & Wilkins, 2012). ???

Adapted from Goodhead D: Physics of radiation action: microscopic features that determine biological consequences. In Hagen U, Harder D, Jung H, et al, editors:

Radiation research 1895-1995, proceedings of the 10th international congress of

radiation research, vol. 2. congress lectures, Wurzburg, 1995, Universitatsdruckerei H Sturtz, p 43.

4

(5)

Hall, E. J. & Giaccia, A. J.Radiobiology for the radiologist. (Wolters Kluwer Health/Lippincott Williams & Wilkins, 2012). Figure 2-2. p 13 (Courtesy of Dr.John Ward.)

(6)

Hall, E. J. & Giaccia, A. J. Radiobiology for the radiologist. (Wolters Kluwer Health/Lippincott Williams & Wilkins, 2012). Figure 2.3

6

(7)

Hall, E. J. & Giaccia, A. J. Radiobiology for the radiologist. (Wolters Kluwer Health/Lippincott Williams & Wilkins, 2012). Figure 2.5 (Courtesy of

Dr. Ester Hammond)

(8)

Hall, E. J. & Giaccia, A. J. Radiobiology for the radiologist. (Wolters Kluwer Health/Lippincott Williams & Wilkins, 2012). Figure 2.15 (Courtesy of Drs. Brewen, Luippold,and Preston.)

8

(9)

Hall, E. J. & Giaccia, A. J. Radiobiology for the radiologist. (Wolters Kluwer

Health/Lippincott Williams & Wilkins, 2012). Figure 2.18 (Courtesy of Dr. Michael Cornforth.)

(10)

Hall, E. J. & Giaccia, A. J. Radiobiology for the radiologist. (Wolters Kluwer Health/Lippincott Williams & Wilkins, 2012). Figure 3.1

10

(11)

Hall, E. J. & Giaccia, A. J. Radiobiology for the radiologist. (Wolters Kluwer Health/Lippincott Williams & Wilkins, 2012). Figure 3.3

(12)

Hall, E. J. & Giaccia, A. J. Radiobiology for the radiologist. (Wolters Kluwer Health/Lippincott Williams & Wilkins, 2012). Figure 3.5

12

(13)

Hall, E. J. & Giaccia, A. J. Radiobiology for the radiologist. (Wolters Kluwer

Health/Lippincott Williams & Wilkins, 2012). Figure 3.4 (From Cornforth MN, Bedford JS.

A quantitative comparison of potentially lethal damage repair and the rejoining of

interphase chromosome breaks in low passage normal human fi broblasts. Radiat Res.

1987;111:385–405, with permission.)

(14)

Wéra, Anne-Catherine, Anne-Catherine Heuskin, Hélène Riquier, Carine Michiels, and Stéphane Lucas. “Low-LET Proton Irradiation of A549 Non-Small Cell Lung Adenocarcinoma Cells: Dose Response and RBE Determination.” Radiation Research 179, no. 3 (March 2013): 273–81. FIG 1.A

15

(15)

Müller, M., Durante, M., Stöcker, H., Merz, F. & Bechmann, I. Modelingradiation effects at the tissue level. EurPhysJ D60, 171 176 (201 0).(graphics kindly provided by Dr.Andrea Ottolenghi, University of Pavia, Italy)

(16)

LNT-modell és jelentősége

Sugárterhelés Biológiai hatás kockázata

17

(17)

Néhány optimalizációs kérdés

 Milyen gyakran végezzünk röntgen/CT-vizsgálatokat dohányzóknál?

 Hogyan tervezzünk meg egy besugárzást?

 konvencionális sugárterápia

 3D-CRT

 IMRT

Hivatkozások

KAPCSOLÓDÓ DOKUMENTUMOK

The effect of the synthetic chalcone derivative 1C on cell growth was determined on mouse T-cell lymphoma cells and human colon adenocarcinoma cells expressing ABCB1 (MDR and

Time and dose dependent development of pericardial edema (A-C) and spine curvature (D-F) for zebrafish embryo irradiation with 6 MV photons (grey), proton plateau (black, dotted)

The efficacy and safety of bevacizumab in addition to platinum- based chemotherapy for the first-line treatment of patients with advanced nonsquamous non-small-cell

(2015) Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer,

(2012) Rare and complex mutations of epidermal growth factor receptor (EGFR) and efficacy of tyrosine kinase inhibitor (TKI) in patients with non-small cell lung cancer

(2006) Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clinical cancer research :

Our study describes the mechanism of vascularization of pulmonary metastases and provides the first experimen- tal evidence that similar to primary human non-small cell lung

radioimmunoassay, the tissue level of PACAP38-like immu- noreactivity (LI) and PACAP27-LI in different primary non- small cell lung cancer, colon tumor samples, and in cardiac